Biomarkers for risk stratification of cardiac causes for chest pain in the West Virginia population

Résumé fourni par la source

The lifetime risk of developing acute coronary syndrome (ACS) is heavily influenced by modifiable factors like smoking, hypertension, diabetes, and lifestyle, as well as non-modifiable factors such as age, sex, and genetics. Chest pain and other symptoms that may represent ACS account for over six million visits annually in the US. Delays in diagnosis and inaccurate risk stratification of chest pain can result in serious morbidity and mortality from ACS and other serious pathologies. ACS carries a massive economic burden, with high direct costs from hospitalizations and significant indirect costs like lost productivity, impacting healthcare systems globally. The economic burden of ACS in the U.S. is substantial, with estimates suggesting total costs ranging from $75 to over $150 billion annually. When patients present with chest pain, their levels of cardiac biomarkers are one piece of the clinical picture, albeit an important one. Together with the history and physical examination, and imaging, these levels help estimate the probability that the patient will experience an adverse clinical outcome. Circulating biomarkers present a promising approach in the research and clinical practice of various diseases as they are minimally invasive, highly cost-effective and provide high specificity. So, the objective of the present study is to analyze a panel of biomarkers that are related to cardiac dysfunction in patients with chest pain as predictive markers of ACS. The cross-sectional study was conducted in patients from Cabell Huntington Hospital, WV. Patients who were referred to the Rapid Access Chest Pain Clinic were enrolled. Patients were selected based on the established inclusion and exclusion criteria. The plasma samples from chest pain patients, in comparison with age-matched controls, were used for the assessment of circulating biomarkers of cardiac dysfunction. We have analyzed the levels of Troponin T (TnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), Myosin-binding protein C (MyBP-C), neopterin and Creatine Kinase-Myocardial Band (CK-MB) in patient plasma samples. Our results showed that there was a significant elevation in these biomarkers in chest pain patients in comparison with healthy controls. The correlation analysis revealed a significant link between these parameters with TnT, the well-established and highly specific predictive markers of cardiac injury and cardiac function decline. This may provide an earlier assessment of overall patient risk and aid in identifying patients with a higher risk of an adverse event. The findings in the present study demonstrate the translational applicability of the proposed biomarker panel to determine and compare the prognostic abilities for early ACS detection. This may also help in diagnosis, risk stratification and guidance of treatment, further allowing management of cardiac function decline and improved health outcomes. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.